 EDISON, N.J., Jan. 05, 2023 GLOBE NEWSWIRE -- Hepion Pharmaceuticals, Inc. NASDAQ:HEPA, a clinical stage biopharmaceutical company focused on Artificial Intelligence AI-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis NASH, hepatocellular carcinoma HCC, and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the NASH-TAG 2023 Conference, which is being held January 5-7, 2022, in Park City, Utah. 